British Journal of Cancer - Volume 98, issue 6

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Cras neque tellus, ornare vel pulvinar luctus, vestibulum malesuada ante. Nullam pellentesque, ipsum vel fermentum tincidunt, velit neque molestie lacus, at iaculis purus mauris in nisl. Nullam vehicula imperdiet auctor. Mauris tempus, leo eget euismod condimentum, erat justo vehicula augue, vitae ornare elit felis nec libero. Etiam et quam sit amet metus dignissim dictum sed vitae purus. Phasellus gravida hendrerit risus vitae euismod. In elementum massa facilisis nulla pulvinar at pharetra leo pellentesque.

Electronic ISSN
1532-1827
Print ISSN
0007-0920

Abstract

Erythropoietin receptor (EpoR) has been reported to be overexpressed in tumours and has raised safety concerns regarding the use of erythropoiesis-stimulating agents (ESAs) to treat anaemia in cancer patients. To investigate the potential for EpoR to be overexpressed in tumours, we have evaluated

Journal: British Journal of Cancer, vol. 98, no. 6, 2008